FY2028 Earnings Forecast for DNLI Issued By HC Wainwright

Key Points

• HC Wainwright has revised its FY2028 earnings estimate for Denali Therapeutics, predicting earnings per share of $0.81, down from a prior estimate of $0.85.
• The consensus estimate for Denali Therapeutics' current full-year earnings stands at ($2.71) per share, while HC Wainwright also projected FY2029 earnings at $2.11 EPS.
• Denali Therapeutics has a market capitalization of $2.07 billion, and its shares saw a trading price drop to $14.14 during midday trading on Thursday.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued on Tuesday, August 12th. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.81 per share for the year, down from their previous forecast of $0.85. HC Wainwright has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2029 earnings at $2.11 EPS.

Other equities analysts also recently issued reports about the company. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Wedbush dropped their target price on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Morgan Stanley decreased their price objective on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating for the company in a report on Monday. Finally, Bank of America decreased their price objective on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $33.62.

Denali Therapeutics Price Performance

Shares of DNLI traded down $0.1650 during trading hours on Thursday, reaching $14.6550. The stock had a trading volume of 500,254 shares, compared to its average volume of 1,407,073. The stock has a market capitalization of $2.14 billion, a PE ratio of -5.23 and a beta of 1.36. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The company's 50-day moving average is $14.30 and its two-hundred day moving average is $15.19.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same period in the prior year, the firm earned ($0.59) EPS.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its position in shares of Denali Therapeutics by 339.6% during the 1st quarter. SG Americas Securities LLC now owns 48,365 shares of the company's stock worth $658,000 after purchasing an additional 37,362 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Denali Therapeutics by 4.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 85,075 shares of the company's stock valued at $1,733,000 after acquiring an additional 3,411 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Denali Therapeutics in the 1st quarter valued at about $254,000. GAMMA Investing LLC lifted its position in Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock valued at $108,000 after acquiring an additional 5,705 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of Denali Therapeutics by 260.9% during the 4th quarter. First Trust Advisors LP now owns 65,442 shares of the company's stock worth $1,334,000 after purchasing an additional 47,308 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the transaction, the insider owned 217,391 shares of the company's stock, valued at $2,952,169.78. This represents a 1.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the transaction, the insider directly owned 242,346 shares in the company, valued at $3,291,058.68. This trade represents a 1.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 501,962 shares of company stock valued at $7,520,799 in the last 90 days. 12.50% of the stock is currently owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.